| Date | Title | Description | |
|---|---|---|---|
| 25 Feb 2026 | Annual Corporate Governance Report | The Company submits the Annual Corporate Governance Report for fiscal year 2025. | Download |
| 25 Feb 2026 | Annual Report regarding remuneration of the members of the Board of Directors | ROVI releases the 2025 annual report regarding remuneration of the members of the Board of Directors. | Download |
| 18 Nov 2025 | On business and financial situation | The Company releases the press release in relation to the signing of the definitive collaboration agreement with Roche for the manufacture of a new medicine in development | Download |
| 02 Oct 2025 | Liquidity and counterparty agreements | Liquidity contract: transactions conducted in the third quarter of 2025 | Download |
| 04 Jul 2025 | Liquidity and counterparty agreements | Liquidity contract: transactions conducted in the second quarter of 2025 | Download |
Pages
| Date | Title | Description | |
|---|---|---|---|
| 08 Oct 2018 | Share capital increases and reductions | Information on the registration in the Commercial Registry of Madrid of the notarial deed regarding the capital increase | Download |
| 05 Oct 2018 | Buy-back programmes, stabilisation and treasury stock | Information about the possibility that Jefferies International Limited carries out stabilisation transactions within the framework of the capital increase excluding pre-emptive subscription rights of the existing shareholders of Laboratorios Farmacéuticos Rovi, S.A. | Download |
| 04 Oct 2018 | Share capital increases and reductions | Directors’ Report and Independent Expert Report related to capital increase excluding preferential subscription rights | Download |
| 04 Oct 2018 | Liquidity contracts and specialists | The Company informs that has temporarily suspended liquidity agreement with JB Capital Markets, Sociedad de Valores, S.A.U. | Download |
| 04 Oct 2018 | Share capital increases and reductions | Information on price fixing and outcome of the private placement related to capital increase addressed to institutional investors, excluding preferential subscription rights | Download |